Pfizer's Sutent fails first Phase III breast cancer trial
This article was originally published in Scrip
Executive Summary
Pfizer's Sutent (sunitinib) has been dealt a significant blow after failing its first Phase III trial in advanced breast cancer, but the company will continue other Phase III trials in the disease, it said.